PALI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Palisade Bio Inc. does not present a strong buy opportunity for a beginner investor with a long-term horizon at this time. While the stock shows some technical bullishness and analysts have positive ratings, the lack of recent news, weak financial performance, and no significant trading signals suggest waiting for clearer catalysts or improved fundamentals.
The technical indicators show a bullish trend with MACD positively expanding, moving averages aligned bullishly (SMA_5 > SMA_20 > SMA_200), and the stock trading near resistance levels (R1: 2.325). However, RSI_6 at 76.503 is in the neutral zone, indicating no clear overbought or oversold signal.
Analysts have initiated coverage with positive ratings and price targets ranging from $5 to $12, citing strong potential for PALI-2108 in the inflammatory bowel disease market. The MACD and moving averages also indicate a bullish technical setup.
The company's financials remain weak, with no revenue, a negative net income of -$8.89M in Q4 2025, and a significant drop in EPS (-89.68% YoY). There are no recent news updates or significant trading trends from hedge funds, insiders, or Congress. Additionally, the stock's short-term trend probabilities suggest limited upside potential in the next week or month.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$8.89M (up 166.12% YoY), and a significant drop in EPS (-89.68% YoY). Gross margin remained at 0%. Overall, the financials indicate weak performance with no revenue generation.
Analysts are bullish on Palisade Bio, with multiple Buy ratings and price targets ranging from $5 to $12. They highlight the potential of PALI-2108 in ulcerative colitis and other inflammatory bowel diseases, despite mixed drug class data in the same indication.
